Quick Order Cart

Cat. No. ARG0696

IRF1 Knockout Ramos Cell Line

  • Product Type:

    Genome-edited Cells

  • Tissue Source:

    Ascites

  • Disease:

    Burkitt lymphoma

  • Gene Species:

    Homo sapiens (Human)

The IRF1 Knockout Ramos Cell Line is a CRISPR/Cas9-edited knockout cell line generated from human Burkitt's lymphoma-derived Ramos B lymphocytes. By disrupting the IRF1 gene, this model enables loss-of-function analysis of a key transcription factor that mediates interferon signaling and immune activation. IRF1 responds to upstream signals including IFNG, IFNA, TNF, and IL-1 via STAT1 and NF-kappaB, and regulates downstream effectors such as HLA class I molecules, CIITA, and OAS1. This knockout cell line is therefore suited for studies of interferon responses, antigen presentation, tumor suppression, and apoptosis in B-cell contexts, with applications in lymphoma research and immunology.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Ramos

    Morphology

    Lymphocyte-like

    Age

    3 years

    Sex of Donor

    Male

    Gene Name

    IRF1

    Gene Species

    Homo sapiens (Human)

    Gene Identifier

    NCBI Gene ID 3659

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

    Pathogens

    Cells tested negative for HIV-1, HBV, and HCV.

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The IRF1 Knockout Ramos Cell Line is a CRISPR/Cas9-edited knockout cell line that provides a loss-of-function model for the IRF1 gene in human B lymphocytes. This gene-disrupted cell line enables targeted investigation of IRF1-dependent processes without the need for sustained drug selection or transient silencing.

The Ramos cell line, derived from a human Burkitt’s lymphoma, is a widely used model for B-cell receptor signaling, apoptosis, and interferon responses. Its B lymphocyte identity supports studies of humoral immunity, including antibody production and antigen presentation, making it relevant for both basic immunology and lymphoma research.

IRF1 encodes a transcription factor activated by interferons (IFNG, IFNA, IFNB), TNF, IL-1, and TLR ligands through upstream mediators STAT1 and NF-kappaB. Upon activation, IRF1 binds ISRE elements to regulate genes involved in antiviral defense (OAS1, PKR), antigen presentation (HLA-A, HLA-B, HLA-C, CIITA, TAP1, PSMB9), chemokine signaling (CXCL10), and apoptosis/cell cycle arrest (CASP1, CDKN1A). IRF1 interacts with cofactors such as STAT1, NF-kappaB p65, IRF8, and histone acetyltransferases (CBP, EP300, PCAF) to orchestrate transcription. Its activity is integrated within JAK-STAT and NF-kappaB pathways, where JAK1/JAK2 phosphorylate STAT1/STAT2, leading to IRF9 complex formation, and IKK/RelA and TBK1/IRF3/IRF7 modules converge. Negative regulation by PIAS1 and SOCS1 ensures tight control.

Disrupting IRF1 in Ramos cells abolishes a central node of interferon signaling, impairing ISRE-driven gene expression and downstream immune functions. This knockout line allows dissection of how IRF1 loss affects B-cell receptor signaling, apoptosis, and antigen presentation, and provides a system to study IRF1’s tumor-suppressive roles in lymphomagenesis, particularly its promotion of cell cycle arrest and apoptosis.

Applications include investigating interferon signaling pathways, tumor suppressor mechanisms, immune modulation, and antigen presentation in B cells. Typical validation techniques include Western blotting, RT-qPCR, RNA-seq, flow cytometry, interferon stimulation assays, ChIP-qPCR, co-immunoprecipitation, and drug sensitivity studies. For further information or to discuss specific experimental applications, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)